Shareholders to Vote on Highly Dilutive Reverse Merger with TELI Pharmaceuticals, Shifting Control and Increasing Equity Pool
TELO sits 20% above its 52-week low of $1.12 on light trading volume (0.1× avg).
Summary
Telomir Pharmaceuticals seeks shareholder approval for a reverse merger with TELI Pharmaceuticals, which will result in existing shareholders owning a minority stake in the combined entity, alongside significant related party conflicts and further equity dilution proposals.
Key Events · M&A and Partnerships · TELO
-
Proposed Reverse Merger with TELI Pharmaceuticals
Telomir Pharmaceuticals plans to merge with private company TELI Pharmaceuticals, Inc., with TELI becoming a wholly-owned subsidiary. This is a fundamental change in the company's structure and control.
-
Significant Shareholder Dilution and Control Shift
Existing Telomir shareholders are projected to own approximately 41% of the combined company on a fully-diluted basis, while TELI shareholders will hold approximately 59%, effectively transferring control.
-
Material Related Party Conflicts of Interest
Telomir's CEO and a major shareholder hold significant beneficial ownership in TELI and MIRALOGX LLC, the licensor of Telomir-1 to both entities, raising governance concerns.
-
Expansion of Equity Incentive Plan and Option Repricing
Shareholders are asked to approve an increase of 5 million shares to the equity incentive plan and allow for the repricing of options, introducing further potential dilution and reducing shareholder protections.
Analysis · TELO · Life Sciences
This preliminary proxy statement outlines a proposed reverse merger with private entity TELI Pharmaceuticals, Inc., which is highly dilutive for existing Telomir Pharmaceuticals shareholders. Post-merger, current TELO shareholders are expected to hold approximately 41% of the combined company on a fully-diluted basis, effectively ceding control to TELI shareholders. This transaction is further complicated by significant related party conflicts of interest, as TELO's CEO and a major shareholder also hold substantial beneficial ownership in TELI and the licensor of Telomir-1. The filing also proposes a substantial increase in the equity incentive plan's share reserve and allows for option repricing, adding to potential future dilution. This critical corporate event follows a recent Nasdaq non-compliance notice, suggesting the merger may be a strategic move to address the company's operational or financial standing, but at a significant cost to current shareholders.
How filings like this one have moved
In the 30 days to Sep 18, 2026, 40.1% of the 362 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.65%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TELO was trading at $1.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $46.1M. The 52-week trading range was $1.12 to $5.40. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.